Breast Defend

New nutraceutical compound formulated specifically to promote and maintain breast health.

Developed by Isaac Eliaz, MD, LAc, MS, this new formula is crafted from eight exclusive, clinically tested compounds, including scientifically supported nutrients, herbs, and medicinal mushrooms.

Each ingredient in BreastDefend is selected on the basis of potency, quality, and scientific research demonstrating unique benefits for breast health. By combining these components, BreastDefend? is a highly effective, safe, and synergistic formula designed to offer cellular support, healthy immune function, and ideal hormonal balance.

Diindolylmethane (DIM), a prominent BreastDefend? ingredient, is a vital compound found in cruciferous vegetables. Scientific research on DIM shows that it promotes breast health by elevating beneficial estrogen metabolites, while reducing ?bad? estrogen levels. DIM has also been shown to inhibit abnormal cell growth and proliferation.

BreastDefend also offers a powerful proprietary botanical blend including Quercetin (98% bioflavanoids), Turmeric rhizome extract (BCM-95®; 95% curcumin), Scutellaria barbata herb extract, and Astragalus membranaceus root extract. BCM 95® is a bio-enhanced form of turmeric root shown to be more bioavailable than standard turmeric root (See study articles below). Similar to DIM, scientific research on each of these components shows positive effects on breast and cellular health.

The final component of the formula is the proprietary mushroom blend containing Coriolus versicolor (Coriolus), Ganoderma lucidum (Reishi), and Phellinus linteus. Grown on a unique botanical blend medium in a controlled indoor environment in the US by USDA Certified Organic growers, the medicinal qualities of these mushrooms are enhanced, further adding to the comprehensive potency of BreastDefend .

Studies

• BCM Study in Spice Board
• Curcugel Study
• BCM-95 A Pilot Cross-Over Study to Evaluate Human Oral Bioavailability (IJPHS)

Serving Size: 2 Capsules
Servings Per Container: 60

Active Ingredients:

• Cellular & Immune Support Proprietary Blend 475 mg
• Scutellaria barbata extract, Tumeric rhizome extract (Curcuma longa, BCM-95; 95% curcumin), Quercetin (98% bioflavinoids), Astragalus membranaceus root extract.
• BreastDefend Proprietary Herbally Enhanced Mushroom Blend 250 mg
• Coriolus versicolor (Coriolus), Ganorderma lucidum (Reishi), Phellinus linteus.
• Diindolymethane (DIM) 100 mg

Inactive Ingredients: Vegetable capsule (natural vegetable cellulose, water), microcrystalline cellulose, magnesium stearate, silicon dioxide.

Recommended Dosage:
As a dietary supplement, take 1-4 capsules, twice daily with food, or as directed by your health care professional.

Caution: As with any dietary supplement containing herbs, if you are nursing or pregnant, or considering pregnancy, please consult your healthcare professional before use of this product.

Breast Defend is 100% vegetarian, allergen and gluten free, and contains no artificial flavors, preservatives or colors.

For more info on this product, please see this Data Sheet

Researchers at Indiana University and Methodist Research Institute have published the dramatic effects of EcoNugenics?s new breast care formula against abnormal breast cells. The study was published online in a peer reviewed medical journal. Lead investigator Dr. Daniel Sliva says, ?The formula we studied inhibits growth of unhealthy breast cells, and suppresses metastatic potential of these cells.?

The all-natural formula combines phytonutrients, botanically enhanced medicinal mushrooms, and antioxidants that work together to provide breast protection.

This potent integrative breast formula can be crucial in the fight against highly invasive breast conditions. ?This unique mixture of ingredients produced strong results at low concentrations, which shows its strength,? says Dr. Isaac Eliaz, developer of the formula. Dr. Eliaz explains, ?The ingredients used promote breast health through critical hormone modulation, cellular protection, and vital immune enhancement.?

Ongoing research on the integrative breast formula continues to show encouraging results, and additional studies are forthcoming.

Read the study here.

References:

1. Lee YK, Park SY, Kim YM, Lee WS, Park OJ. AMP kinase/cyclooxygenase-2 pathway regulates proliferation and apoptosis of cancer cells treated with quercetin. Exp Mol Med. 2009 Mar 31;41(3):201-7.
2. Chien SY, Wu YC, Chung JG, Yang JS, Lu HF, Tsou MF, Wood WG, Kuo SJ, Chen DR. Quercetin-induced apoptosis acts through mitochondrial- and caspase-3-dependent pathways in human breast cancer MDA-MB-231 cells. Hum Exp Toxicol. 2009 Aug;28(8):493-503.
3. V clav¡kov  R, Kondrov  E, Ehrlichov  M, Boumendjel A, Kov r J, Stopka P, Soucek P, Gut I. The effect of flavonoid derivatives on doxorubicin transport and metabolism. Bioorg Med Chem. 2008 Feb 15;16(4):2034-42.
4. Lin CW, Hou WC, Shen SC, Juan SH, Ko CH, Wang LM, Chen YC. Quercetin inhibition of tumor invasion via suppressing PKC delta/ERK/AP-1-dependent matrix metalloproteinase-9 activation in breast carcinoma cells. Carcinogenesis. 2008 Sep;29(9):1807-15.
5. Choi EJ, Bae SM, Ahn WS. Antintiproliferative effects of quercetin through cell cycle arrest and apoptosis in human breast cancer MDA-MB-453 cells. Arch Pharm Res. 2008 Oct;31(10):1281-5.
6. Chiu TL, Su CC. Curcumin inhibits proliferation and migration by increasing the Bax to Bcl-2 ratio and decreasing NF-kappaBp65 expression in breast cancer MDA-MB-231 cells. Int J Mol Med. 2009 Apr;23(4):469-75.
7. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 2008 Oct 8;269(2):199-225.
8. Kim HI, Huang H, Cheepala S, Huang S, Chung J. Curcumin inhibition of integrin (alpha6beta4)-dependent breast cancer cell motility and invasion. Cancer Prev Res (Phila Pa). 2008 Oct;1(5):385-91.
9. Karunagaran D, Rashmi R, Kumar TR. Induction of apoptosis by curcumin and its implications for cancer therapy. Curr Cancer Drug Targets. 2005 Mar;5(2):117-29.
10. Auyeung KK, Cho CH, Ko JK. A novel anticancer effect of Astragalus saponins: Transcriptional activation of NSAID-activated gene. Int J Cancer. 2009 Feb 27.
11. Cho WC, Leung KN. In vitro and in vivo anti-tumor effects of Astragalus membranaceus. Cancer Lett. 2007 Jul 8;252(1):43-54.
12. Fong S, Shoemaker M, Cadaoas J, Lo A, Liao W, Tagliaferri M, Cohen I, Shtivelman E. Molecular mechanisms underlying selective cytotoxic activity of BZL101, an extract of Scutellaria barbata, towards breast cancer cells. Cancer Biol Ther. 2008 Apr;7(4):577-86.
13. Rugo H, Shtivelman E, Perez A, Vogel C, Franco S, Tan Chiu E, Melisko M, Tagliaferri M, Cohen I, Shoemaker M, Tran Z, Tripathy D. Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer. Breast Cancer Res Treat. 2007 Sep;105(1):17-28.
14. Rahman KM, Ali S, Aboukameel A, Sarkar SH, Wang Z, Philip PA, Sakr WA, Raz A. Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Mol Cancer Ther. 2007 Oct;6(10):2757-65.
15. Degner SC, Papoutsis AJ, Selmin O, Romagnolo DF.Targeting of aryl hydrocarbon receptor-mediated activation of cyclooxygenase-2 expression by the indole-3-carbinol metabolite 3,3'-diindolylmethane in breast cancer cells. J Nutr. 2009 Jan;139(1):26-32.
16. Wan JM, Sit WH, Louie JC. Polysaccharopeptide enhances the anticancer activity of doxorubicin and etoposide on human breast cancer cells ZR-75-30. Int J Oncol. 2008 Mar;32(3):689-99.
17. Ho CY, Kim CF, Leung KN, Fung KP, Tse TF, Chan H, Lau CB. Differential anti-tumor activity of coriolus versicolor (Yunzhi) extract through p53- and/or Bcl-2-dependent apoptotic pathway in human breast cancer cells. Cancer Biol Ther. 2005 Jun;4(6):638-44.
18. Jiang J, Grieb B, Thyagarajan A, Sliva D. Ganoderic acids suppress growth and invasive behavior of breast cancer cells by modulating AP-1 and NF-kappaB signaling. Int J Mol Med. 2008 May;21(5):577-84.
19. Jiang J, Slivova V, Sliva D. Ganoderma lucidum inhibits proliferation of human breast cancer cells by down-regulation of estrogen receptor and NF-kappaB signaling. Int J Oncol. 2006 Sep;29(3):695-703.
20. Thyagarajan A, Jiang J, Hopf A, Adamec J, Sliva D. Inhibition of oxidative stress-induced invasiveness of cancer cells by Ganoderma lucidum is mediated through the suppression of interleukin-8 secretion. Int J Mol Med. 2006 Oct;18(4):657-64.
21. Jiang J, Slivova V, Harvey K, Valachovicova T, Sliva D. Ganoderma lucidum suppresses growth of breast cancer cells through the inhibition of Akt/NF-kappaB signaling. Nutr Cancer. 2004;49(2):209-16.
22. Hu H, Ahn NS, Yang X, Lee YS, Kang KS. Ganoderma lucidum extract induces cell cycle arrest and apoptosis in MCF-7 human breast cancer cell. Int J Cancer. 2002 Nov 20;102(3):250-3.
23. Sliva D, Labarrere C, Slivova V, Sedlak M, Lloyd FP Jr, Ho NW. Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells. Biochem Biophys Res Commun. 2002 Nov 8;298(4):603-12.
24. Sliva D, Jedinak A, Kawasaki J, Harvey K, Slivova V. Phellinus linteus suppresses growth, angiogenesis and invasive behaviour of breast cancer cells through the inhibition of AKT signaling. Br J Cancer. 2008 Apr 22;98(8):1348-56.